Current | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000

Celera Genomics And Compaq Canada Form Exclusive Marketing Distribution Agreement

Rockville, MD and London, Ontario - November 07, 2001

Compaq Canada Corp. together with Celera Genomics (NYSE:CRA), an Applera Corporation business, today announced a unique initiative, enhancing the ability for the non-profit public and private research community in Canada to get access to Celera’s genomic databases and analysis tools through Compaq as distributor.

Compaq Canada has entered into an exclusive agreement to be the preferred distributor of access to the Celera Discovery System (CDS)—Celera’s proprietary bioinformatics platform of database content, analysis and visualization tools—to the non-profit research community in Canada. The CDS includes detailed, annotated data derived from Celera’s groundbreaking work in sequencing the complete human genome and complete mouse genome, as well as integrated publicly available data. This agreement is intended to facilitate quick and reliable access to both the Celera genomic databases and Celera and Compaq Canada technology solutions, with the goal of assisting Canada’s research community in its quest to discover future medical and genomic breakthroughs.

“This is a remarkable strategic opportunity for Compaq Canada and Celera, to make the Celera Discovery System, the world’s foremost genomic research system, available to a much wider community in Canada,” said David Booth, President and Managing Director, Compaq Canada Corp. “Working with a leading innovator like Celera inspires all of us at Compaq to push the envelope of innovation in our own technology.”

“J. Craig Venter, Ph.D., Celera’s president and chief scientific officer, said, “Through this unique agreement, Compaq and Celera have committed to furthering leading edge genomic research by providing Canadian researchers and health care providers the data and bioinformatics tools in the Celera Discovery System.”

Celera announced the first assembly of the human genome in June 2000 and has continued to validate and refine its assembly since then. Access to assembled and annotated genomes and the bioinformatics data mining tools has become crucial to research programs in academic settings. The Compaq/Celera distribution arrangement broadens access to Celera’s pioneering research, helping to bring the most advanced comparative genomics capabilities within reach of the Canadian non-profit research community. The ability to compare human and mouse genome data using CDS should allow researchers to make important discoveries and predictions in the regulation of human genes.

“Celera’s assembling the complete human genome sequence is without doubt one of the most significant scientific advances of the 21st century,” said Dr. Alan Bernstein, President, Canadian Institutes of Health Research. “Our ability to access their database and research tools, coupled with Compaq’s technology support, will greatly enhance our research efforts. This partnership will have direct and tangible benefit in allowing researchers throughout Canada and the world to expand their genomic research.”

Under the terms of the agreement, qualified research affiliates that subscribe will gain access to Celera’s Proprietary Databases including the Celera assembled and annotated human and mouse genome sequence data. Subscribers will also have access to Celera’s public/third party databases and a suite of analysis, data mining, visualization, and comparative genomics tools.

This extended agreement builds on the current relationship between Compaq and Celera. With Compaq’s assistance and support, Celera has established one of the most powerful non-government supercomputing facilities in the world, featuring 800 interconnected Compaq Alpha-based, true 64-bit computer systems, each of which is capable of performing more than 250 billion sequence comparisons per hour.

While Celera has made and continues to make the CDS available to researchers in Canada, Compaq has established a team to support the Celera initiative, which has been designed to help make the CDS more accessible through a Compaq-managed program. Qualifying research organizations have three options to acquire Celera database licensing. As many researchers in Canada will require additional, dedicated hardware to support use of the CDS platform, Compaq has developed a number of product bundles that incorporate suitable hardware with the Celera database subscription. For those researchers that do not require bundled offerings, Compaq has established a program, whereby a percentage of the cost of Compaq-related and eligible products and services acquired by the researcher can be offset against the cost of the CDS subscription. Eligible researchers may also purchase subscriptions directly from Compaq and Celera.

Organizational Backgrounds
Applera Corporation comprises two operating groups. The Celera Genomics Group, headquartered in Rockville, MD, is engaged principally in integrating advanced technologies to create therapeutic discovery and development capabilities for internal use and for its customers and collaborators. Celera’s businesses are its online information business and its therapeutics discovery business. The online information business is a leading provider of information based on the human genome and other biological and medical information. Through the therapeutic discovery business, Celera intends to leverage its genomic and proteomic capabilities to identify drug targets and diagnostic marker candidates, and to discover novel therapeutic candidates. The Applied Biosystems Group (NYSE:ABI) develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.6 billion during fiscal 2001. Celera Diagnostics has been established as a joint venture between Applied Biosystems and Celera Genomics. This new venture is focused on discovery, development and commercialization of novel diagnostic tests. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available on the World Wide Web at www.applera.com, or by telephoning 800.762.6923. Information about Celera is available on the World Wide Web at www.celera.com.

Compaq Computer Corporation, a Fortune Global 100 company, is a leading global provider of technology and solutions. Compaq designs, develops, manufactures, and markets hardware, software, solutions, and services, including industry-leading enterprise computing solutions, fault-tolerant business-critical solutions, and communications products, commercial desktop and portable products, and consumer PCs that are sold in more than 200 countries. Information on Compaq and its products and services is available at www.compaq.ca.

With headquarters and distribution facilities in Richmond Hill, Compaq Canada Corp. employs a workforce of 3,500 people located in 41 offices across Canada, including Vancouver, Edmonton, Calgary, Regina, Winnipeg, London, Mississauga, Markham, Ottawa, Montreal, Quebec City, Moncton, Halifax and St. John's. With the exception of its larger scale technologies and services, Compaq products and services are sold and supported through a network of more than 1,200 marketing partners across the country.

Compaq and the Compaq logo are trademarks of Compaq Information Technologies Group, L.P. This press release may contain forward-looking statements that involve risks, uncertainties and assumptions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Risks, uncertainties and assumptions include the possibility that the Hewlett-Packard/Compaq merger does not close or that the companies may be required to modify aspects of the transaction to achieve regulatory approval or that prior to the closing of the proposed merger, the businesses of the companies suffer due to uncertainty; the market for the sale of certain products and services may not develop as expected; that development of these products and services may not proceed as planned; that Compaq and Hewlett-Packard are unable to transition customers, successfully execute their integration strategies, or achieve planned synergies; other risks that are described from time to time in Compaq and Hewlett-Packard's Securities and Exchange Commission reports (including but not limited to Compaq's annual report on Form 10-K for the year ended December 31, 2000, HP's annual report on Form 10-K for the year ended October 31, 2000, and subsequently filed reports). If any of these risks or uncertainties materializes or any of these assumptions proves incorrect, Compaq's results could differ materially from Compaq's expectations in these statements. Compaq assumes no obligation and does not intend to update these forward-looking statements.


Notice To Readers: Celera's press releases, presentations and printed remarks are included on this website for historical purposes only. The information contained in these documents should be considered accurate only as of the date of the relevant document. This information may change over time, and therefore visitors to this website should not assume that the information contained in these documents remains accurate at a later time. We do not have any current intention to update any of the information in these documents.